GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monopar Therapeutics Inc (NAS:MNPR) » Definitions » Pretax Margin %

MNPR (Monopar Therapeutics) Pretax Margin % : % (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Monopar Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Monopar Therapeutics's Pre-Tax Income for the three months ended in Sep. 2024 was $-1.30 Mil. Monopar Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Monopar Therapeutics's pretax margin for the quarter that ended in Sep. 2024 was %.

The historical rank and industry rank for Monopar Therapeutics's Pretax Margin % or its related term are showing as below:


MNPR's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -148.6
* Ranked among companies with meaningful Pretax Margin % only.

Monopar Therapeutics Pretax Margin % Historical Data

The historical data trend for Monopar Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monopar Therapeutics Pretax Margin % Chart

Monopar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial - - - - -

Monopar Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Monopar Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Monopar Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Monopar Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Monopar Therapeutics's Pretax Margin % falls into.



Monopar Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Monopar Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-8.402/0
= %

Monopar Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-1.304/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Monopar Therapeutics  (NAS:MNPR) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Monopar Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Monopar Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Monopar Therapeutics Business Description

Traded in Other Exchanges
Address
1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Executives
Andrew Cittadine officer: Chief Operating Officer C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Michael J Brown director C/O EURONET WORLDWIDE, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 300, LEAWOOD KS 66211
Arthur J Klausner director ONE PALMER SQUARE, PRINCETON NJ 08542
Raymond Anderson director C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Kim R Tsuchimoto officer: Chief Financial Officer C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Chandler Robinson director, officer: Chief Executive Officer C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Patrice Rioux other: Acting Chief Medical Officer C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Christopher M Starr director C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Filho Jose Octavio Pinto Costa officer: Chief Medical Officer C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Tactic Pharma Llc 10 percent owner C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Diane Hendricks 10 percent owner C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Karl Leo 10 percent owner C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Kirsten Anderson officer: SVP, Clinical Development C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Gem Pharmaceuticals Llc 10 percent owner C/O 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Tacticgem Llc 10 percent owner 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091